Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 44

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 44
---
00.
The transaction closed in April 2022.

On January 11, 2024, we consummated a registered
direct offering of 1,468,000 common shares and 32,000 pre-funded warrants at a price of $1.60 per common share and $1.5999 per pre-funded
warrant share and a simultaneous private placement of unregistered common warrants to purchase an aggregate of up to 1,500,000 common
shares. The unregistered common warrants have an exercise price of $1.60 per share, are immediately exercisable and have a 5-year term
from the issuance date.

The privately placed
securities above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities
Act and Rule 506 of Regulation D promulgated thereunder since, among other things, the transactions did not involve a public offering
and the securities were acquired for investment purposes only and not with a view to or for sale in connection with any distribution
thereof.

Additionally, since January
2022, we have granted share options and RSU’s to employees, directors, consultants and service providers under our Executive Stock
Option and Restricted Share Unit Plans. There are currently an aggregate of 151,813 stock options and RSU’s outstanding, with exercise
prices ranging from $23.40 to $646.74 per share.

Item 8. Exhibits and Financial Statement Schedules.

(a) Exhibits.See the Exhibit Index attached
to this registration statement, which is incorporated by reference herein.

(b) Financial Statement Schedules. Schedules
not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial
statements or notes thereto.

<div align='center'>II-2</div>

Item 9. Undertakings.

| (a) | The                                       
 undersigned Registrant hereby undertakes: |

| (1) | To                                                                                          
 file, during any period in which offers or sales are being made, a post-effective amendment 
 to this registration statement:                                                             |

| i. | To                                                                         
 include any prospectus required by section 10(a)(3) of the Securities Act; |

| ii. | To                                                                                                   
 reflect in the prospectus any facts or events arising after the effective date of the registration   
 statement (or the most recent post-effective amendment thereof) which, individually                  
 or in the aggregate, represent a fundamental